The startup, which has already raised more than half a billion dollars, released Phase 2 results that could position its drug ...

Denali’s medicine and a similar one from Calico Life Sciences and AbbVie were not much different than a placebo, bringing the ...

The three-year partnership is another example of Vertex’s interest in improving on Casgevy, its CRISPR medicine for sickle cell and beta thalassemia.

Results from a study called Mariposa found a regimen of Rybrevant and Lazcluze helped patients with a common form of advanced ...